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Introduction
Opportunities to use genomic information to guide cancer therapy are rapidly emerging. Genomic alterations have been associated with drug sensitivity and resistance. For example, amplification of HER2 predicts responses to HER2-targeted therapy in patients with breast cancer. Emerging results suggest that other alterations, such as PIK3CA mutations, may modulate sensitivity to established therapies such as trastuzumab and endocrine therapy as well as to investigational agents and over-the-counter medications (1) (2) (3) (4) . Therefore, genomic characterization of breast cancer tumors may identify aberrations that can be pursued as potential therapeutic targets.
In patients with metastatic cancer biomarkers are often assessed in archived primary tumor specimens. However recurrent breast tumors may differ from primary tumors on the molecular level, and tumors may also evolve with treatment. In previous studies, we and others showed discordances between primary and metastatic tumors in standard-of-care markers estrogen receptor (ER), progesterone receptor (PR), and HER2 (5, 6) as well as other markers such as PIK3CA (7, 8) . Differences in standard biomarkers between primary and metastatic tumors have been associated with differences in outcomes; thus, comparisons of primary and metastatic or recurrent tumors may help optimize patient management (5, 6) . The goal of this study was to conduct a comprehensive, next-generation sequencing-based analysis comparing 
Patients and Methods

Identification of patient samples
Paraffin blocks from formalin-fixed primary breast cancer specimens and/or biopsy specimens of recurrent or metastatic tumors were obtained at the Hospital 
Genomic profiling
We performed comprehensive genome profiling on FFPE samples by using a Table 1) , and the genes were sequenced to an average depth of 380X uniquely mapped reads. The full coding region was sequenced. The coverage is listed in Supplementary Table 2. Paired end were sequenced (49 x 49 cycles) with the HiSeq2000 system (Illumina, San Diego, CA). Sequence data were mapped to the reference human genome (hg19) with BWA alignment software ( (11) and processed with the publicly available SAMtools ( (12) software packages Picard (http://picard.sourceforge.net) and GATK (13) . Genomic base substitutions and indels were detected with custom tools optimized for mutation calling in heterogeneous tumor samples, on the basis of statistical modeling of sequence quality scores and local sequence assembly. Base substitution detection was performed using a Bayesian methodology, which allows detection of novel somatic mutations at low MAF and increased sensitivity for mutations at hotspot sites ((11)) through the incorporation of tissue-specific prior expectations:
where P(R|F) is evaluated with a multinomial distribution of the observed allele counts using empirically observed error rates and P(F=0) is the prior expectation of mutation in the tumor type. Novel mutations causing premature stop codons (nonsense mutations), novel frameshift mutations, and novel mutations affecting splices sites (-2 to +2) were considered to be likely functional truncation mutations of tumor suppressor genes.
Genes significantly enriched in truncation mutations in cancer genome surveys were considered to be tumor suppressor genes (13) .
To detect indels, de-novo local assembly in each targeted exon was performed using the de-Bruijn approach (12) . Candidate calls were filtered using a series of quality metrics, including strand bias, read location bias, and a custom database of sequencing artifacts derived from normal controls. Germline DNA was not available therefore somatic alterations were determined computationally. Germline alterations were identified and filtered using dbSNP (version 135) (13) and subsequently annotated for known and likely somatic mutations using the COSMIC database (version 62).
Detection of copy-number alterations (CNAs) was performed by obtaining a log-ratio profile of the sample by normalizing the sequence coverage obtained at all exons against a process-matched normal control. The profile was segmented and interpreted using allele frequencies of ~1,800 additional genome-wide SNPs to estimate tumor purity and copy number based on established methods ((14-16) by fitting parameters of the equation lrseg~N(log2p*Cseg+(1−p)*2p*tumorploidy+(1−p)*2), where lrseg, Cseg, and p are the log-ratios and copy numbers at each segment and sample purity respectively. Focal amplifications are called at segments with ≥6 copies and homozygous deletions at 0 copies, in samples with purity >20%. This threshold (≥6 copies) is referred to as the "reporting threshold" in the results and discussion. Genomic rearrangements were detected by clustering chimeric reads mapping to targeted introns.
Variations were filtered by using the dbSNP archive The median disease-free survival times from diagnosis and from surgery were performed using the R package "survival". Fisher's exact test was used to study the association of the tumor subtype with the alteration of TP53 or PIK3CA.
Results
Patient and Sample Characteristics
The study cohort consisted of 43 patients who had both primary and recurrent/ metastatic tumor tissue available. The median age at breast cancer diagnosis In addition, three unmatched primary-tumor samples, one unmatched lymph node metastasis sample, and eight unmatched recurrence samples (three from one patient) were analyzed. These samples were included because little is known about the spectrum of genomic alterations in patients with metastatic or recurrent breast cancer.
Genomic alterations
Among the 74 samples, we identified alterations in 55 genes. Every sample Table 2 ; genes altered in the primary tumors are listed in Figure   1A , and genes altered in recurrent or metastatic tumors are listed in Figure 1B 
Comparison of primary tumors and recurrent/metastatic tumors
To look for evidence of molecular evolution, we compared genomic alterations in In the 33 matched primary-recurrent/metastatic tumor pairs, 97 (86·6%) of the 112 somatic mutations detected were concordant. Ninety-nine (62·3%) of 159 copy number alterations reported were concordant, 37 (23·3%) were concordant but below the reporting threshold in one of the matched samples, and 23 (14·5%) were discordant. Three (37·5%) of eight primary-tumor-LRR pairs had at least one genomic discordance, and 18 (72%) of 25 primary-tumor-metastasis pairs had at least one genomic discordance (p=0·1057). 
NGS allowed identification of multiple copy number alterations, including HER2
gains. This suggests that targeted exome sequencing should be considered as an alternate strategy for HER2 assessment. NGS can also detect HER2 mutations, which have recently been identified in connection with potential benefits of anti-HER2 agents (17) . In addition to oncogenes widely recognized to be amplified in breast cancer, such as HER2, FGFR, CCND1, MYC, MDM2, and CDK4, we found copy number gains in the antiapoptosis gene MCL1 in almost a third of the samples. MCL1 has recently been reported to be amplified in multiple cancer types including breast cancer (18) . An MCL1 copy number gain may influence a tumor's sensitivity to standard chemotherapeutic agents (19) . Because cancer cells with an MCL1 amplification are dependent on MCL1 for survival, MCL1
inhibitors are now being actively pursued (18) . Thus, MCL1 may be an important therapeutic target in metastatic breast cancer. 
